{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Current+ART&page=4",
    "query": {
      "intervention": "Current ART",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 89,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Current+ART&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Current+ART&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-12T10:45:17.594Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01013935",
      "title": "A Spanish-Language Intervention to Enhance Routine HIV Patient Care Delivery [CARE+ Spanish]",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "CARE+ Spanish computer counseling session",
          "type": "OTHER"
        },
        {
          "name": "CARE+ Spanish brief computer risk assessment session",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "New York University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 556,
      "start_date": "2010-06",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2022-10-28",
      "last_synced_at": "2026-11-12T10:45:17.594Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01013935"
    },
    {
      "nct_id": "NCT03299049",
      "title": "Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Cabotegravir Tablets",
          "type": "DRUG"
        },
        {
          "name": "Rilpivirine Tablets",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir Injectable Suspension",
          "type": "DRUG"
        },
        {
          "name": "Rilpivirine Injectable Suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1049,
      "start_date": "2017-10-27",
      "completion_date": "2029-12-31",
      "has_results": true,
      "last_update_posted_date": "2026-10-21",
      "last_synced_at": "2026-11-12T10:45:17.594Z",
      "location_count": 43,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03299049"
    },
    {
      "nct_id": "NCT02263326",
      "title": "Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "dolutegravir",
          "type": "DRUG"
        },
        {
          "name": "lamivudine",
          "type": "DRUG"
        },
        {
          "name": "Continue current antiretroviral regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Babafemi Taiwo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2014-12",
      "completion_date": "2017-09",
      "has_results": true,
      "last_update_posted_date": "2019-10-14",
      "last_synced_at": "2026-11-12T10:45:17.594Z",
      "location_count": 7,
      "location_summary": "San Diego, California • Atlanta, Georgia • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02263326"
    },
    {
      "nct_id": "NCT00299897",
      "title": "SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections",
        "Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "SP01A",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Samaritan Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 60,
      "start_date": "2006-03",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2006-10-27",
      "last_synced_at": "2026-11-12T10:45:17.594Z",
      "location_count": 5,
      "location_summary": "Beverly Hills, California • Fort Lauderdale, Florida • Orlando, Florida + 2 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00299897"
    },
    {
      "nct_id": "NCT03976258",
      "title": "Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "HIV Infection",
        "Opioid-use Disorder",
        "Cardiovascular Diseases"
      ],
      "interventions": [
        {
          "name": "buprenorphine/naloxone",
          "type": "DRUG"
        },
        {
          "name": "Methadone",
          "type": "DRUG"
        },
        {
          "name": "Naltrexone Injection",
          "type": "DRUG"
        },
        {
          "name": "Heroin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MetroHealth Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 190,
      "start_date": "2017-07-14",
      "completion_date": "2022-12-31",
      "has_results": false,
      "last_update_posted_date": "2023-10-02",
      "last_synced_at": "2026-11-12T10:45:17.594Z",
      "location_count": 2,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03976258"
    },
    {
      "nct_id": "NCT00735072",
      "title": "Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infection"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Maraviroc",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2008-09",
      "completion_date": "2010-07",
      "has_results": true,
      "last_update_posted_date": "2020-08-17",
      "last_synced_at": "2026-11-12T10:45:17.594Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Stanford, California • Chicago, Illinois + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00735072"
    },
    {
      "nct_id": "NCT07434479",
      "title": "A Virtual Reality Mindfulness Application for Aggression in Schizophrenia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia Disorder",
        "Schizoaffecitve Disorder",
        "Aggression"
      ],
      "interventions": [
        {
          "name": "Mindfulness-Based Virtual Reality Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Manhattan Psychiatric Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 58,
      "start_date": "2026-06-05",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-11-12T10:45:17.594Z",
      "location_count": 2,
      "location_summary": "New York, New York • White Plains, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "White Plains",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07434479"
    },
    {
      "nct_id": "NCT02227277",
      "title": "Reducing Proviral HIV DNA With Interferon-a",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV",
        "HIV/AIDS"
      ],
      "interventions": [
        {
          "name": "Peg-IFN-α2b",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Wistar Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 54,
      "start_date": "2015-02-11",
      "completion_date": "2018-07-24",
      "has_results": false,
      "last_update_posted_date": "2018-04-05",
      "last_synced_at": "2026-11-12T10:45:17.594Z",
      "location_count": 3,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02227277"
    },
    {
      "nct_id": "NCT07524361",
      "title": "Taekwondo Program for Preventing Falls in Older Adults",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Taekwondo-based Fall Prevention Exercise Condition",
        "Fall Prevention Education Control Condition"
      ],
      "interventions": [
        {
          "name": "Fall prevention exercise using Taekwondo",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Live Strong and Safe Program on Fall Prevention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2026-01-13",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-11-12T10:45:17.594Z",
      "location_count": 1,
      "location_summary": "Columbia, South Carolina",
      "locations": [
        {
          "city": "Columbia",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07524361"
    },
    {
      "nct_id": "NCT07209267",
      "title": "Baricitinib Curative Repression of HIV-1",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infection",
        "HIV"
      ],
      "interventions": [
        {
          "name": "Antiretroviral Therapy (ART)",
          "type": "DRUG"
        },
        {
          "name": "Baricitinib (LY3009104) 2 mg",
          "type": "DRUG"
        },
        {
          "name": "Baricitinib (LY3009104) 4 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 35,
      "start_date": "2026-10",
      "completion_date": "2028-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-11-12T10:45:17.594Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07209267"
    }
  ]
}